A Phase 2/3 interventional study of Radiofrequency ablation and Cytokine-induced killer cells in Cholangiocarcinoma, sponsored by The First People's Hospital of Changzhou. Active, not recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-01.
Sponsored by The First People's Hospital of Changzhou · Phase 2/3, Interventional, and Treatment
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.
930 studies on the registry are indexed under Cholangiocarcinoma; 292 are open to participants now.
This study's enrollment of 50 is close to the median of 50 across 698 interventional studies indexed under Cholangiocarcinoma.
Browse Cholangiocarcinoma studies →The First People's Hospital of Changzhou is the lead sponsor of 28 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergo radiofrequency ablation alone.
Procedure: Radiofrequency ablation
Autologous cytokine-induced killer cells were transfer via venous one week after RFA
Procedure: Radiofrequency ablation · Biological: Cytokine-induced killer cells
Radiofrequency ablation is performed percutaneously under CT/US guidance
Also known as: RFA
The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Also known as: CIK
Recurrence-free survival
Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.
Time frame: 1 year
Adverse events
Adverse events related to RFA and CIK treatments.
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytokine-Induced Killer Cells
The First People's Hospital of Changzhou